Biocon posts more than twofold increase in Q4 profit
Bengaluru: Biocon, an Indian biopharmaceutical company, has reported a more than twofold increase in its fourth-quarter profit, driven by robust demand for its generics and biosimilar products in its key U.S. and European markets.
The company's consolidated net profit rose 153% to 3.45 billion rupees ($40.43 million), after an exceptional item, for the three months ended March 31 from a year ago.
"Our biosimilars continue to build impressive shares in global markets with four biosimilars recording sales of $200 million each in FY25," Biocon Group Chairperson Kiran Mazumdar-Shaw said in a statement on Thursday.
Biosimilars are copies of costlier biological drugs for treating major illnesses such as cancer, rheumatoid arthritis and psoriasis.
Biocon's total quarterly revenue rose 12.3% to 44.54 billion rupees.
As per Reuters report, revenue from its generic drugs business, which declined in the past few quarters, rose 46% to 10.48 billion rupees in the fourth quarter, aided by new product launches, especially in the oncology segment.
The company expects to see a recovery in its active pharmaceutical ingredient (API) business in fiscal 2026.
APIs are key components in a drug that produce the intended therapeutic effects.
Quarterly revenue in the company's biosimilars business rose 4.5%.
Biocon said its focus is also on expanding its diabetes and obesity drugs portfolio, the demand for which has skyrocketed in global markets.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.